Remove 2018 Remove Community Remove Government Remove Provider
article thumbnail

Green Practice News: April 2025

My Green Doctor

Todd Sack concludes that, “ the medical office waiting room appears to be an accepted, time-efficient, and effective site to communicate knowledge on climate change and health. ” from 2000 to 2018 among people over 65 years old. Let My Green Doctor guide you through the content of this breakthrough and peer-reviewed report.

article thumbnail

Approaches for Quelling Stigma related to COVID-19

BMJ

A multilayered view of stigmatizing discourses lays the foundation for eliciting a series of suggestions for quelling stigma, to be implemented at the individual, community, and national levels, as suggested by the WHO. Yet, as Tenkorang 7 made the point, it is simply not enough to only implement approaches at the community level.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law

Koblitz — You know a court decision is going to be worth reading when the judges compare FDA’s regulatory governance of flavored e-cigarettes to a Shakespearean gaslighting. By David B. Clissold & Sara W. FDA said randomized clinical trials could be used, but so could observational studies with respect to cessation data.

article thumbnail

Supreme Court Finds CMS’ Reduction of Medicare Hospital Outpatient Payment Rates for 340B Hospitals was Not Authorized by Statute

FDA Law

Kirschenbaum — In 2017, the Centers for Medicare & Medicaid Services (“CMS”) issued a final rule to significantly decrease the rate the government will reimburse 340B hospitals in 2018 for outpatient prescription drugs from average sales price (“ASP”) plus 6% to ASP minus 22.5%. By Faraz Siddiqui & Alan M. 52494 (Nov.

article thumbnail

District Court Interprets EKRA

FDA Law

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. His job was governed by an employment contract that contained both salary provisions and restrictive covenants.

article thumbnail

District Court Interprets EKRA

FDA Law

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. His job was governed by an employment contract that contained both salary provisions and restrictive covenants.

article thumbnail

New Breakthrough Devices Program Guidance: Expanding Opportunities for Medical Product Innovations

FDA Law

FDA previously released the final guidance document in December 2018 outlining the program’s principles, features, designation criteria, and other considerations. Additionally, the 2022 draft guidance suggested the addition of a new section to the 2018 guidance on reducing disparities in health and healthcare. Emphasis added.)

Medical 53